Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a large drop in short interest in May. As of May 15th, there was short interest totaling 387 shares, a drop of 91.3% from the April 30th total of 4,431 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 30,829 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC acquired a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma at the end of the most recent reporting period. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Trading Up 2.0%

Shares of Matinas Biopharma stock traded up $0.02 during mid-day trading on Friday, reaching $0.81. 40,360 shares of the stock were exchanged, compared to its average volume of 96,038. The company has a market cap of $5.19 million, a price-to-earnings ratio of -0.41 and a beta of 1.61. The firm has a 50-day simple moving average of $0.59 and a 200 day simple moving average of $0.67. Matinas Biopharma has a fifty-two week low of $0.48 and a fifty-two week high of $3.09.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.30) earnings per share for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.